Iron is required to transport oxygen through haemoglobin in red blood cells (RBCs) and oxidize cells through cytochrome. Iron deficiency is a common cause of anaemia. Iron drugs are used to treat people with iron deficiency.
Due to the COVID-19 pandemic, the global Iron Drugs market size is estimated to be worth US$ 3912.8 million in 2022 and is forecast to a readjusted size of US$ 6264 million by 2030 with a CAGR of 6.8% during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Iron Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Iron Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
In terms of geographic regions, the North Americas accounted for the major share in the market in 2018. The growing awareness of iron drugs in the region is the major cause for the growth of the market.
This report focuses on Iron Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Iron Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
Global Iron Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Oral Drug
IV Drug
Segment by Application
Hospital
Drugstore
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Allergan
AMAG Pharmaceuticals
Daiichi Sankyo
Pharmacosmos
Vifor Pharma
Galenica
Nippon Shinyaku
Sanofi
Wanbang Biopharmaceutical
